AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16970531 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture for 60 seconds
Number of subjects: 18
Study 16970531 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual acupuncture for 180 seconds
Number of subjects: 18
Study 14629635 — intervention group
Group type: EXPERIMENTAL
Intervention: Introduction of 'pain-advisers' in the study area (SA)
Number of subjects: 53
Study 14629635 — intervention group
Group type: COMPARATOR
Intervention: Control area (CA) without 'pain-advisers'
Number of subjects: 53
Study 10644899 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol patches (Estraderm TTS; 0.8 mg)
Number of subjects: 2
Study 10644899 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 2
Study 10644899 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol alone
Number of subjects: 2
Study 10644899 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (AMPH; 10 mg p.o.)
Number of subjects: 2
Study 9288292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal provocation test with ammonium persulphate (APS)
Number of subjects: 40
Study 9288292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal provocation test with dandruff
Number of subjects: 40
Study 9288292 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal provocation test
Number of subjects: 40
Study 9288292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal provocation test with ammonium thioglycolate (ATG)
Number of subjects: 40
Study 7689827 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser treatment
Number of subjects: 267
Study 7689827 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 267
Study 3463727 — intervention group
Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1% zinc citrate and 0.5% 2,4,4' trichloro-2'-hydroxydiphenyl ether
Number of subjects: 0
Study 3463727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30185583 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC) oxygen therapy alone
Number of subjects: 600
Study 30185583 — intervention group
Group type: COMPARATOR
Intervention: High-flow nasal cannula (HFNC) oxygen therapy with non-invasive ventilation (NIV) sessions
Number of subjects: 600
Study 26655425 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendamustine plus rituximab (90 mg/m2 on days 1 and 2, rituximab 375 mg/m2 on day 1)
Number of subjects: 219
Study 26655425 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine plus rituximab (25 mg/m2 on days 1-3, rituximab 375 mg/m2 on day 1)
Number of subjects: 219
Study 25001947 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual melatonin 3 mg
Number of subjects: 99
Study 25001947 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual melatonin 10 mg
Number of subjects: 99
Study 25001947 — intervention group
Group type: COMPARATOR
Intervention: sublingual placebo
Number of subjects: 99
Study 22543913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening using algorithms to interpret CA125 and ultrasound imaging
Number of subjects: 202638
Study 22543913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian cancer screening with well-defined, centrally coordinated management of screen-detected abnormalities
Number of subjects: 202638
Study 20375422 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g of fish oil emulsion/kg infusion for 14 days
Number of subjects: 23
Study 20375422 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 g of fish oil/kg oral capsules after infusion
Number of subjects: 23
Study 20375422 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion (placebo) for 14 days
Number of subjects: 23
Study 20375422 — intervention group
Group type: COMPARATOR
Intervention: Paraffin wax oral capsules (placebo) after infusion
Number of subjects: 23
Study 18415808 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (800 microg daily, 6 months)
Number of subjects: 19
Study 18415808 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (30 mg daily, 3 weeks)
Number of subjects: 19
Study 18415808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15942291 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Cycle of Breathing Techniques (ACBT)
Number of subjects: 20
Study 15942291 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella
Number of subjects: 20
Study 12501127 — intervention group
Group type: EXPERIMENTAL
Intervention: +Calanolide A
Number of subjects: 47
Study 10411559 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (i.v. administration in therapeutic doses)
Number of subjects: 0
Study 10411559 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (in vitro)
Number of subjects: 0
Study 10411559 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (in vivo)
Number of subjects: 0
Study 7480549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 0.5 mg
Number of subjects: 12
Study 7480549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5 mg
Number of subjects: 12
Study 7480549 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam 15 mg
Number of subjects: 12
Study 7480549 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam 45 mg
Number of subjects: 12
Study 7480549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7480549 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam (high dose) vs Adinazolam (high dose)
Number of subjects: 12
Study 2344898 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 68
Study 2344898 — intervention group
Group type: COMPARATOR
Intervention: Quinidine
Number of subjects: 68
Study 7006345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin at a dosage of 500 mg b.i.d.
Number of subjects: 100
Study 7006345 — intervention group
Group type: COMPARATOR
Intervention: Nalidixic acid at a dosage of 1 g q.i.d.
Number of subjects: 100
Study 31647325 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual on-site monitoring
Number of subjects: 4371
Study 31647325 — intervention group
Group type: COMPARATOR
Intervention: No on-site monitoring
Number of subjects: 4371
Study 30644124 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPIT recovery program delivered by nurses
Number of subjects: 386
Study 28548228 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM (near-infrared 839/595 nm)
Number of subjects: 20
Study 28548228 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PBM (595 nm)
Number of subjects: 20
Study 28548228 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM (30 minutes MAL-incubation)
Number of subjects: 20
Study 28548228 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PBM (30 minutes MAL-incubation)
Number of subjects: 20
Study 28548228 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM (90 minutes MAL-incubation)
Number of subjects: 20
Study 28548228 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PBM (90 minutes MAL-incubation)
Number of subjects: 20
Study 28548228 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM (180 minutes MAL-incubation)
Number of subjects: 20
Study 28548228 — intervention group
Group type: COMPARATOR
Intervention: Placebo-PBM (180 minutes MAL-incubation)
Number of subjects: 20
Study 28548228 — intervention group
Group type: EXPERIMENTAL
Intervention: PBM and Placebo-PBM
Number of subjects: 20
Study 26217089 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk prediction scoring model (based on age ≥ 40 years, total bilirubin ≥ 171 μmol/L, prothrombin activity 40%‐60%, hepatitis B virus DNA > 107 copies/mL)
Number of subjects: 1457
Study 23001540 — intervention group
Group type: EXPERIMENTAL
Intervention: Resinous extract from Commiphora swynnertonii at 400 mg/kg bodyweight
Number of subjects: 80
Study 23001540 — intervention group
Group type: EXPERIMENTAL
Intervention: Resinous extract from Commiphora swynnertonii at 800 mg/kg bodyweight
Number of subjects: 80
Study 23001540 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoccidial drug
Number of subjects: 80
Study 23001540 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 80
Study 21124045 — intervention group
Group type: EXPERIMENTAL
Intervention: Transtympanic steroid injection (4 courses of methylprednisolone after conventional treatment)
Number of subjects: 76
Study 21124045 — intervention group
Group type: COMPARATOR
Intervention: Conventional steroid treatment
Number of subjects: 76
Study 19747585 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training (2x5‐min/day, Frequency: 20Hz; amplitude: 2‐4mm)
Number of subjects: 8
Study 19747585 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (no vibration training)
Number of subjects: 8
Study 19747585 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 8
Study 19747585 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration training
Number of subjects: 8
Study 16847610 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmastoidal galvanic vestibular stimulation (GVS) at two different intensities
Number of subjects: 0
Study 16847610 — intervention group
Group type: COMPARATOR
Intervention: Normal vision
Number of subjects: 0
Study 16847610 — intervention group
Group type: EXPERIMENTAL
Intervention: Blurring vision
Number of subjects: 0
Study 15672278 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUS lesion guided biopsy
Number of subjects: 217
Study 15672278 — intervention group
Group type: COMPARATOR
Intervention: Systematic sextant biopsy
Number of subjects: 217
Study 15672278 — intervention group
Group type: EXPERIMENTAL
Intervention: Both biopsy strategies
Number of subjects: 217
Study 11372906 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care services
Number of subjects: 0
Study 11372906 — intervention group
Group type: COMPARATOR
Intervention: Traditional pharmacy care
Number of subjects: 0
Study 9230805 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication (complete wrap)
Number of subjects: 39
Study 9230805 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet fundoplication (partial wrap)
Number of subjects: 39
Study 8431045 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous extrapleural intercostal nerve block
Number of subjects: 20
Study 8431045 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural morphine
Number of subjects: 20
Study 2890442 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium 0.12 mg.kg‐1
Number of subjects: 60
Study 2890442 — intervention group
Group type: EXPERIMENTAL
Intervention: vecuronium 0.12 mg.kg‐1
Number of subjects: 60
Study 2890442 — intervention group
Group type: EXPERIMENTAL
Intervention: atracurium 0.4 mg.kg‐1
Number of subjects: 60
Study 2890442 — intervention group
Group type: EXPERIMENTAL
Intervention: pancuronium‐metocurine mixture (0.4 mg + 1.6 mg/ml): 1 ml/10 kg
Number of subjects: 60
Study 31286293 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference pegfilgrastim (PG)
Number of subjects: 250
Study 31286293 — intervention group
Group type: COMPARATOR
Intervention: Potentially biosimilar test product
Number of subjects: 250
Study 26856250 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone after 2 weeks
Number of subjects: 183
Study 26856250 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone after 9 months (CATIE confirmatory analysis)
Number of subjects: 183
Study 26337017 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee polyphenol extract (CPE) beverage
Number of subjects: 19
Study 26337017 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 19
Study 23324995 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin (4 mg/day)
Number of subjects: 101
Study 23324995 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (20 mg/day)
Number of subjects: 101
Study 21965490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmucosal herbal periodontal patch (THPP) for three days
Number of subjects: 53
Study 21965490 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches (PP) for three days
Number of subjects: 53
Study 19828907 — intervention group
Group type: EXPERIMENTAL
Intervention: American ginseng supplementation (500 mg daily for 4 months)
Number of subjects: 25
Study 19828907 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 25
Study 16735951 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol therapy
Number of subjects: 6
Study 16735951 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol and testosterone therapy
Number of subjects: 6
Study 16735951 — intervention group
Group type: COMPARATOR
Intervention: No hormone therapy (untreated postmenopausal women)
Number of subjects: 6
Study 16735951 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 6
Study 15026296 — intervention group
Group type: EXPERIMENTAL
Intervention: Lyme disease vaccination
Number of subjects: 745
Study 11303077 — intervention group
Group type: EXPERIMENTAL
Intervention: Gulf veterans
Number of subjects: 4795
Study 11303077 — intervention group
Group type: COMPARATOR
Intervention: Non-Gulf veterans
Number of subjects: 4795
Study 9595867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg
Number of subjects: 1473
Study 9595867 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg
Number of subjects: 1473
Study 9595867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1473
Study 8085692 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy plus radiation therapy
Number of subjects: 0
Study 8085692 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon combined with psoralen plus ultraviolet A light therapy
Number of subjects: 0
Study 8085692 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine analogs and retinoids
Number of subjects: 0
Study 8085692 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferons
Number of subjects: 0
Study 8085692 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopheresis therapy
Number of subjects: 0
Study 8085692 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 fusion toxins and several antibody conjugates
Number of subjects: 0
Study 3256648 — intervention group
Group type: EXPERIMENTAL
Intervention: Preparatory vulval cleansing before urine specimen collection
Number of subjects: 316
Study 3256648 — intervention group
Group type: COMPARATOR
Intervention: No preparatory vulval cleansing before urine specimen collection
Number of subjects: 316
Study 31955921 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine care plus a web‐based self‐management intervention including individual e‐coaching and group meetings over a 3‐month intervention period, followed by e‐coaching over a 6‐month maintenance period.
Number of subjects: 99
Study 31955921 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control group).
Number of subjects: 99
Study 30470147 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action liquid (20 ml)
Number of subjects: 20
Study 30470147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28128748 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration cytology (FNAC)
Number of subjects: 629
Study 28128748 — intervention group
Group type: COMPARATOR
Intervention: Fine-needle non-aspiration cytology (FNNAC)
Number of subjects: 629
Study 25871803 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine exposure
Number of subjects: 19
Study 25871803 — intervention group
Group type: EXPERIMENTAL
Intervention: Prematurity, opioid exposure and neonatal pain
Number of subjects: 19
Study 23323867 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenal infusion of donor feces after an initial vancomycin regimen (500 mg orally four times per day for 4 days) followed by bowel lavage and subsequent infusion.
Number of subjects: 16
Study 23323867 — intervention group
Group type: COMPARATOR
Intervention: Standard vancomycin regimen (500 mg orally four times per day for 14 days).
Number of subjects: 16
Study 23323867 — intervention group
Group type: COMPARATOR
Intervention: Standard vancomycin regimen with bowel lavage.
Number of subjects: 16
Study 21112925 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral weight control (BWC) intervention for 16 weeks with 4 biweekly maintenance sessions
Number of subjects: 86
Study 21112925 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater parent self-monitoring during the intervention
Number of subjects: 86
Study 21112925 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater parent pressure to eat
Number of subjects: 86
Study 20067164 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective randomized study on 559 diabetics from Timişoara
Number of subjects: 1184
Study 20067164 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective descriptive study on 625 diabetics from Petroşani
Number of subjects: 1184
Study 17472115 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 2
Study 17472115 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 2
Study 14709942 — intervention group
Group type: EXPERIMENTAL
Intervention: SRI treatment for 8 weeks
Number of subjects: 19
Study 14709942 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 sex-matched and age-matched individuals)
Number of subjects: 19
Study 11309437 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin (30 mg/day) for 3 years
Number of subjects: 1166
Study 11309437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1166
Study 9344429 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated taste group (same taste stimuli)
Number of subjects: 0
Study 9344429 — intervention group
Group type: COMPARATOR
Intervention: Changing taste group (different taste stimuli)
Number of subjects: 0
Study 7875957 — intervention group
Group type: EXPERIMENTAL
Intervention: Protirelin tartrate 4 mg/die i.m.
Number of subjects: 20
Study 7875957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 2839020 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (n = 127)
Number of subjects: 253
Study 2839020 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 126)
Number of subjects: 253
Study 31638960 — intervention group
Group type: COMPARATOR
Intervention: Intravenous TXA (1000 mg administered intravenously twice, just before surgery and 6 hours after)
Number of subjects: 77
Study 31638960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TXA (1000 mg of intra-articular TXA for each knee plus intravenous TXA as above)
Number of subjects: 77
Study 31638960 — intervention group
Group type: COMPARATOR
Intervention: Intravenous TXA
Number of subjects: 77
Study 31638960 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined TXA
Number of subjects: 77
Study 28577752 — intervention group
Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with 10 cc of air for 1.5 hours
Number of subjects: 3616
Study 28577752 — intervention group
Group type: COMPARATOR
Intervention: TR Band hemostasis with 13 cc of air for 4 hours
Number of subjects: 3616
Study 28577752 — intervention group
Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with 10 cc of air for 3 hours
Number of subjects: 3616
Study 28577752 — intervention group
Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with 10 cc of air for 2 hours
Number of subjects: 3616
Study 28577752 — intervention group
Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with less than 13 cc of air
Number of subjects: 3616
Study 28577752 — intervention group
Group type: EXPERIMENTAL
Intervention: TR Band hemostasis with more than 1.5 hours
Number of subjects: 3616
Study 26268494 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro‐movement sensitive mattress sleep monitoring system (MSMSMS)
Number of subjects: 61
Study 26268494 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 61
Study 22752758 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home portable monitoring (PMhome)
Number of subjects: 43
Study 22752758 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous PM and polysomnography (PSG+PM)
Number of subjects: 43
Study 22752758 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 43
Study 21231926 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy plus pharmacotherapy (IPT)
Number of subjects: 124
Study 21231926 — intervention group
Group type: COMPARATOR
Intervention: Medication plus clinical management (CM)
Number of subjects: 124
Study 18436027 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine buccal infiltration
Number of subjects: 31
Study 18436027 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine infiltrations
Number of subjects: 31
Study 18436027 — intervention group
Group type: COMPARATOR
Intervention: IANB using 2% lidocaine 1:80,000 epinephrine
Number of subjects: 31
Study 18436027 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal infiltration with articaine
Number of subjects: 31
Study 22694733 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid-free (SF) immunosuppression
Number of subjects: 130
Study 22694733 — intervention group
Group type: COMPARATOR
Intervention: Steroid-based (SB) immunosuppression
Number of subjects: 130
Study 15754600 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluidotherapy (heat at 46.7 degrees C - 48.9 degrees C and tactile stimulation)
Number of subjects: 21
Study 15754600 — intervention group
Group type: EXPERIMENTAL
Intervention: Tactile stimulation alone
Number of subjects: 21
Study 15754600 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 21
Study 12610738 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide (10(‐2) g/ml to 10(‐8) g/ml)
Number of subjects: 22
Study 12610738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (400 microg/day for 3 weeks)
Number of subjects: 22
Study 12610738 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dose-cutaneous response effect
Number of subjects: 22
Study 12610738 — intervention group
Group type: COMPARATOR
Intervention: Methacholine bronchial challenge testing
Number of subjects: 22
Study 12610738 — intervention group
Group type: COMPARATOR
Intervention: Serum cortisol
Number of subjects: 22
Study 10196655 — intervention group
Group type: EXPERIMENTAL
Intervention: Bismuth subgallate
Number of subjects: 204